Experimental cancer drug trial halted after early testing
NCT ID NCT03144661
Summary
This early-stage study tested the safety and highest tolerable dose of an experimental drug called INCB062079 in people with advanced liver cancer and other solid tumors. The trial enrolled 25 participants whose cancers had progressed after standard treatments and was designed to find the safest dose level. The study was terminated early, and participants needed to take additional medications alongside the experimental drug.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVARIAN CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Cliniques Universitaires Saint-Luc
Brussels, 1200, Belgium
-
Institut Jules Bordet
Brussels, 1000, Belgium
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
-
University Hospital (UZ) Leuven
Leuven, 3000, Belgium
-
University of Alabama
Birmingham, Alabama, 35294, United States
-
University of Toledo Medical Center
Toledo, Ohio, 43614, United States
Conditions
Explore the condition pages connected to this study.